We’re thrilled to share that the Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, a potentially transformative investigational #GeneTherapy for people with #FrontotemporalDementia with GRN mutations, is now recruiting patients in the United States at The Ohio State University Wexner Medical Center. Learn more: https://lnkd.in/gcEQATSJ #FTD #Biotech #AviadoBio
AviadoBio
Biotechnology Research
London, England 10,646 followers
A revolution in gene therapy for neurodegenerative disorders.
About us
At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
- Website
-
http://www.aviadobio.com
External link for AviadoBio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
20 Water Street
London, England E14 9GG, GB
Employees at AviadoBio
Updates
-
Our CEO, Lisa Deschamps, was in Washington, D.C. for the Alliance for Regenerative Medicine Congressional Fly-In. We loved learning about the latest updates in regenerative medicine and hearing from the event’s Keynote Speaker, Dr. Nicole Verdun.
Our 2024 Cell & Gene Congressional Fly-In came to a close yesterday, marking our most successful Fly-In yet! Throughout the course of Tuesday, we covered: ➡ 100+ offices ➡ 23 states Thank you to all of our advocates who came out this week to show support for patients who rely on the promise of cell and gene therapies. We especially thank our speakers and the 100+ offices from Congress and the administration for taking the time to hear our priorities. #CGFlyIn24
-
On #ResearchAppreciationDay and every day, we share our gratitude for our team of #Aviators who are working relentlessly to bring transformative medicines to people who need them. Learn more about AviadoBio here www.aviadobio.com #GeneTherapy #FTD #ALS
-
Today and every day we recognize the people affected by #ALS around the world. At AviadoBio, we are on a mission to develop potentially life-changing medicines for people with neurodegenerative disorders like ALS. Learn more about what you can do to support ALS research: https://lnkd.in/g3hTiWHs #ALSMNDWithoutBorders
-
#ICYMI: Brad Loncar from BiotechTV joined our CEO, Lisa Deschamps at our new Canary Wharf headquarters to learn more about our #GeneTherapy platform in development for neurodegenerative diseases including #FrontotemporalDementia (#FTD) and #ALS. Watch the full video here: https://lnkd.in/gjsUhCkq #Biotech
-
Join our CEO Lisa Deschamps at LSEG (London Stock Exchange Group)'s The Future of Healthcare Investment Forum for a roundtable discussion on Neuropsychology and Neurodegeneration and emerging approaches to treatment, moderated by Kevin Grogan, Managing Editor Europe, Scrip Citeline Commercial. View the full agenda: herehttps://lnkd.in/giaWVhEn #frontotemporaldementia #aviadobio
-
Thank you to Brad Loncar with BiotechTV for stopping by our new headquarters to speak with our CEO, Lisa Deschamps! Learn more about our direct delivery approach and our investigational gene therapies in development for #FrontotemporalDementia (#FTD) and #ALS below. #GeneTherapy #Biotech
𝐅𝐫𝐨𝐦 𝐋𝐨𝐧𝐝𝐨𝐧: Canary Wharf based AviadoBio entered the clinic in April with the world's first-in-human intrathalamic delivered gene therapy for a type of dementia. CEO Lisa Deschamps describes this now clinical program for frontotemporal dementia, and Aviado's broader platform for using gene therapies and silencers against neurodegenerative diseases. Full video: https://lnkd.in/gjsUhCkq BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
We’re attending the European Network to Cure #ALS meeting next week! We look forward to gaining valuable perspectives as we work to develop a potentially life-changing #genetherapy for ALS. Learn more: https://www.encals.eu/ #ENCALS
-
AviadoBio reposted this
We are getting everything ready and bags are being packed - our Genetic ALS & FTD Community Summit is starting Friday! We wish to publicly thank our generous event sponsors Biogen, Prevail Therapeutics, ALS United Greater Chicago, The Association for Frontotemporal Degeneration (AFTD), ALS Network, Alector, and recent addition AviadoBio! We could not have planned this event without our event partners, ALS Hope Foundation, NEALS, Northwestern Medicine's Les Turner ALS Center, and our local host, Les Turner ALS Foundation, who have shepherded this with us with kindness and commitment to providing our community a welcoming space.
-
Our COO Graeme Fielder is looking forward to joining the panel at One Nucleus BioWednesday London this evening. He’ll be discussing Deal-making for Cell and Gene Therapy Companies - what makes these different to deals for small molecules or other types of therapies and what are the top priorities for those looking to invest in or acquire cell or gene therapy businesses. He’s joined by a great line up of speakers Claire Smith Bristows, Jodie Albutt, Quell Therapeutics, Nuno Alves, PhD, Astellas Pharma and Pedro Correa de Sampaio, Neobe Therapeutics. Find out more https://lnkd.in/d6YY7__Y